Tokyo, April 14 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061245) titled 'Biomarker Study with ctDNA Analysis in Induction Chemo-radiation Therapy Followed by Surgery with Perioperative Immunotherapy for Resectable Stage Discreate N2 IIIA-B Non-small Cell Lung Cancer (SQUAT-TR4 Study) (WJOG12119LTR4)' on April 14.
Study Type:
Observational
Primary Sponsor:
Institute - West Japan Oncology Group
Condition:
Condition - Non-small cell lung cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to explore the utility of circulating tumor DNA (ctDNA) as a biomarker for predicting pathological response preoperatively and for predicting recurrence, using previously collected blood samples from participants enrolled in the Phase II trial titled "A Phase II Study of Quadruple-Modality Therapy Incorporating Induction Chemoradiotherapy Plus Perioperative Immunotherapy for Resectable Discrete N2 Stage IIIA-B Non-Small Cell Lung Cancer" (WJOG12119L).
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients who were enrolled in WJOG12119L and, at the time of enrollment in the present study, had not withdrawn their informed consent for that trial.
Key exclusion criteria - Patients deemed inappropriate for inclusion by the attending physician.
Target Size - 30
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 03 Month 31 Day
Anticipated trial start date - 2026 Year 05 Month 01 Day
Last follow-up date - 2028 Year 04 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070076
Disclaimer: Curated by HT Syndication.
